• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$132.17 $2.46 (1.90%)

REAL-TIME: Last trade at

Regeneron Pharmaceuticals, Inc...

NASDAQ:REGN

Jump to this page for:

Related Resources

Orbimed's $3.4B Filing: 2 Stocks It And Other Healthcare Funds Bought In Q1, And Other Trades

5/24/2012 by Seeking Alpha

How to Play an Arena Delay

5/22/2012 by DailyFinance

How High Can Medivation Fly?

5/15/2012 by DailyFinance

Shorts Are Piling Into These Stocks. Should You Be Worried?

5/14/2012 by DailyFinance

Has XOMA Become the Perfect Stock?

5/10/2012 by DailyFinance

Regeneron Dips on Safety Concern Over Gout Treatment [UPDATE]

5/9/2012 by Minyanville

UPDATE: FDA: Regeneron Drug Offers 'Small' Benefit In Gout

5/4/2012 by Smart Money

Regeneron Dips on Safety Concern Over Gout Treatment

5/4/2012 by Minyanville

Why These 2 Biotechs Are Soaring

5/3/2012 by DailyFinance

Seeing Black Gives Regeneron a 9% Pop

4/27/2012 by DailyFinance

Top Analyst Upgrades & Downgrades (AET, AEM, APD, ALU, MDRX, AMZN, AMCC, BIDU, CBG, CTCT, DECK, EBAY

4/27/2012 by 247wallst

Eylea Drives Regeneron to Profit - Analyst Blog

4/27/2012 by Nasdaq

Eylea Drives Regeneron to Profit - Analyst Blog

4/27/2012 by Nasdaq

Regeneron Shares Jump on Strong Sales of Eye Drug

4/26/2012 by Minyanville

TIP SHEET: Janus Fund Tries To Manage Risk Of Drug Stocks

4/26/2012 by Smart Money

24/7 Wall St. Closing Bell (GD, ABB, HOG, COP, S, ALU, MO, PEP, TLAB, XOM, AET, BMY, BG, JBLU, LIZ,

4/26/2012 by 247wallst

Why Regeneron Pharmaceuticals Shares Popped

4/26/2012 by DailyFinance

TIP SHEET: Janus Fund Tries To Manage Risk Of Drug Stocks

4/25/2012 by Smart Money

Top Analyst Upgrades & Downgrades (ARMH, STD, BBVA, PRSS, CBS, DRQ, FFIV, GE, GRPN, MSFT, NSM, PCLN,

4/23/2012 by 247wallst

24/7 Wall St. Closing Bell (GE, FFIV, GRPN, PGR, REGN, CHKP, COP, DHI, ETN, HAS, PCH, XRX, AMLN, LSI

4/23/2012 by 247wallst

Regeneron Eyes a New 52-Week High: Can It Head Higher?

4/18/2012 by DailyFinance

The Highest-Paid Hedge Fund Managers

4/13/2012 by DailyFinance

Is Johnson & Johnson a Cash King?

4/7/2012 by DailyFinance

Priority Review for Zaltrap - Analyst Blog

4/5/2012 by Nasdaq

Still Neutral on Ardea Biosciences - Analyst Blog

4/4/2012 by Nasdaq

The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Sanofi, Pfizer, Bayer and Toyota Motor

3/30/2012 by Nasdaq

Unlike March Madness, This ACC Is a Winner

3/30/2012 by DailyFinance

Pipeline Progress at Regeneron - Analyst Blog

3/29/2012 by Nasdaq

The Zacks Analyst Blog Highlights: Amgen, Sanofi, Regeneron, Alnylam and Coach - Press Releases

3/28/2012 by Nasdaq

Drug Approved, Sales Battle Begins

3/28/2012 by DailyFinance

Encouraging Data on Amgen Candidate - Analyst Blog

3/27/2012 by Nasdaq

Sanofy, Regeneron Get Positive News from Drug Trials (SNY, REGN)

3/26/2012 by 247wallst

Sanofi Drug Lowered Cholesterol Levels In Study

3/26/2012 by Smart Money

3 Dow Stocks That Soared With the Market

3/26/2012 by DailyFinance

Regeneron's Drug Dramatically Lowers Bad Cholesterol Levels for Lipitor Users

3/26/2012 by Minyanville

Regeneron's Cholesterol Drug to Get a Closer Look

3/22/2012 by Minyanville

Make Money in "Pure Growth" Stocks the Easy Way

3/21/2012 by DailyFinance

Edwards Life's Valve Data To Highlight Upcoming Heart Meeting

3/21/2012 by Smart Money

2 Big Reasons for This Drug's Second Look

3/19/2012 by DailyFinance

A Drug Class Back From the Dead?

3/13/2012 by DailyFinance
See More Articles...